Clinical Trials · NCT02316899
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 500
- Start date
- Oct 2014
- Locations
- 61 sites, Japan
- Primary endpoint
- Responder rate of Global assessment of relief of IBS symptoms during 12 weeks.